ArticleFrontiers in systems neuroscience2012
Histamine H3 receptor antagonists/inverse agonists on cognitive and motor processes: relevance to Alzheimer's disease, ADHD, schizophrenia, and drug abuse.
Article in Frontiers in systems neuroscience, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 80 citations in OpenAlex.
- Efficacy and Safety of Histamine H3 Receptor Antagonist/Inverse Agonist Including Betahistine for Schizophrenia: A Systematic Review and Meta-Analysis.Neuropsychopharmacology reports · 2025Pooled it
- Antidepressants for cognitive impairment in schizophrenia--a systematic review and meta-analysis.Schizophrenia research · 2014Pooled it
- Potential enhancing effects of histamine H₁ agonism/H₃ antagonism on working memory assessed by performance and bold response in healthy volunteers.British journal of pharmacology · 2013Trial
- Design, synthesis and pharmacological evaluation of novel 2-aryloxazole-based HMolecular diversity · 2026Article
- Biological factors contributing to divergent cortical abnormalities in adolescent and adult psychiatric disorders.Translational psychiatry · 2026Article
- Neurotransmitter Systems in Alzheimer's Disease.Current issues in molecular biology · 2026Review
- Histamine HInflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Review
- Working memory processes and the histamine-3 receptor in schizophrenia: a [Psychopharmacology · 2025Article
- Neural, genetic, and cognitive signatures of creativity.Communications biology · 2024Article
- Histamine-3 Receptor Availability and Glutamate Levels in the Brain: A PET-1H-MRS Study of Patients With Schizophrenia and Healthy Controls.The international journal of neuropsychopharmacology · 2024Article
- Tackling Neuroinflammation in Cognitive Disorders with Single-targeted and Multi-targeted Histamine H3 Receptor Modulators.Current topics in medicinal chemistry · 2024Review
- The histamine system and cognitive function: An in vivo H3 receptor PET imaging study in healthy volunteers and patients with schizophrenia.Journal of psychopharmacology (Oxford, England) · 2023Article
- Binding of the Dual-Action Anti-Parkinsonian Drug AG-0029 to Dopamine DMolecular pharmaceutics · 2022Article
- Pharmacokinetic Modeling of [Molecular pharmaceutics · 2022Article
- Medicinal chemistry perspectives of 1,2,3,4-tetrahydroisoquinoline analogs - biological activities and SAR studies.RSC advances · 2021Review
- Pitolisant in an Adolescent with Prader-Willi Syndrome.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2021Article
- PS4DR: a multimodal workflow for identification and prioritization of drugs based on pathway signatures.BMC bioinformatics · 2020Article
- Alzheimer's Disease Pharmacotherapy in Relation to Cholinergic System Involvement.Biomolecules · 2019Review
- 7-Pyrrolidinethoxy-4'-Methoxyisoflavone Prevents Amyloid β-Induced Injury by Regulating Histamine H3 Receptor-Mediated cAMP/CREB and AKT/GSK3β Pathways.Frontiers in neuroscience · 2019Article
- Histamine N-methyltransferase regulates aggression and the sleep-wake cycle.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Histamine H3 receptor (H3R) antagonists/inverse agonists possess potential to treat diverse disease states of the central nervous system (CNS). Cognitive dysfunction and motor impairments are the hallmark of multifarious neurodegenerative and/or psychiatric disorders. This review presents the various neurobiological/neurochemical evidences available so far following H3R antagonists in the pathophysiology of Alzheimer's disease (AD), attention-deficit hyperactivity disorder (ADHD), schizophrenia, and drug abuse each of which is accompanied by deficits of some aspects of cognitive and/or motor functions. Whether the H3R inverse agonism modulates the neurochemical basis underlying the disease condition or affects only the cognitive/motor component of the disease process is discussed with the aim to provide a rationale for their use in diverse disease states that are interlinked and are accompanied by some common motor, cognitive and attentional deficits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.